ERNA Eterna Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: ERNA

Price (delayed)

$2.16

Market cap

$11.69M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.08

Enterprise value

$41.86M

Highlights
The company's revenue rose by 33% QoQ
The quick ratio has soared by 70% from the previous quarter but it has contracted by 14% YoY
Eterna Therapeutics's EPS has increased by 49% YoY but it has decreased by 3% from the previous quarter
ERNA's gross profit has dropped by 143% since the previous quarter
The gross margin has plunged by 83% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OCX OGEN OLMA OMER

Key stats

What are the main financial stats of ERNA
Market
Shares outstanding
5.41M
Market cap
$11.69M
Enterprise value
$41.86M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.23
Price to sales (P/S)
168.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
615.58
Earnings
Revenue
$68,000
EBIT
-$21.06M
EBITDA
-$19.93M
Free cash flow
-$20.43M
Per share
EPS
-$4.08
Free cash flow per share
-$3.84
Book value per share
$0.41
Revenue per share
$0.01
TBVPS
$8.86
Balance sheet
Total assets
$49.13M
Total liabilities
$46.9M
Debt
$41.84M
Equity
$2.23M
Working capital
$3.03M
Liquidity
Debt to equity
18.74
Current ratio
1.46
Quick ratio
1.84
Net debt/EBITDA
-1.51
Margins
EBITDA margin
-29,314.7%
Gross margin
-247.1%
Net margin
-31,864.7%
Operating margin
-31,572.1%
Efficiency
Return on assets
-53.1%
Return on equity
-509%
Return on invested capital
-40.4%
Return on capital employed
-49.5%
Return on sales
-30,966.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ERNA stock price

How has the Eterna Therapeutics stock price performed over time
Intraday
0.47%
1 week
-2.26%
1 month
-6.09%
1 year
-33.74%
YTD
20.33%
QTD
-10%

Financial performance

How have Eterna Therapeutics's revenue and profit performed over time
Revenue
$68,000
Gross profit
-$168,000
Operating income
-$21.47M
Net income
-$21.67M
Gross margin
-247.1%
Net margin
-31,864.7%
ERNA's gross profit has dropped by 143% since the previous quarter
The gross margin has plunged by 83% from the previous quarter
The operating income rose by 38% YoY
The company's revenue rose by 33% QoQ

Growth

What is Eterna Therapeutics's growth rate over time

Valuation

What is Eterna Therapeutics stock price valuation
P/E
N/A
P/B
5.23
P/S
168.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
615.58
Eterna Therapeutics's EPS has increased by 49% YoY but it has decreased by 3% from the previous quarter
ERNA's equity has dropped by 82% year-on-year and by 37% since the previous quarter
ERNA's P/B is 58% above its last 4 quarters average of 3.3 but 15% below its 5-year quarterly average of 6.1
The company's revenue rose by 33% QoQ

Efficiency

How efficient is Eterna Therapeutics business performance
ERNA's return on equity has dropped by 174% year-on-year and by 71% since the previous quarter
The company's return on invested capital has surged by 97% YoY and by 31% QoQ
The ROA has grown by 43% YoY and by 9% from the previous quarter
Eterna Therapeutics's ROS has increased by 21% from the previous quarter

Dividends

What is ERNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ERNA.

Financial health

How did Eterna Therapeutics financials performed over time
Eterna Therapeutics's total assets is 4.8% higher than its total liabilities
Eterna Therapeutics's total assets has surged by 121% YoY but it has decreased by 6% QoQ
Eterna Therapeutics's current ratio has surged by 100% QoQ but it has decreased by 18% YoY
ERNA's equity has dropped by 82% year-on-year and by 37% since the previous quarter
The debt to equity has soared by 69% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.